



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 892 048 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
20.01.1999 Bulletin 1999/03

(21) Application number: 98113003.2

(22) Date of filing: 13.07.1998

(51) Int. Cl.<sup>6</sup>: **C12N 15/12**, C12N 15/11,  
C07K 14/47, C12N 15/85,  
C12N 5/10, A01K 67/027,  
G01N 33/50, A61K 38/17,  
A61K 48/00, C12Q 1/68,  
C12P 21/08

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: 14.07.1997 US 52402 P  
01.08.1997 US 54491 P  
18.08.1997 US 56338 P

(71) Applicant: **UNIVERSITY OF OTTAWA**  
Ottawa, Ontario K1N 6N5 (CA)

(72) Inventors:  
• **Korneluk, Robert**  
Ottawa Ontario K1G 2L8 (CA)

• **Tamai, Katsuyuki**  
Nagano Prefecture (JP)  
• **Liston, Peter**  
Ottawa, Ontario K1S 2H2 (CA)  
• **Mackenzie, Alexander E.**  
Ottawa, Ontario K1M 1A3 (CA)  
• **Balrd, Stephen**  
Ottawa Ontario K1Y 0S5 (CA)

(74) Representative:  
**Vossius, Volker, Dr. et al**  
**Dr. Volker Vossius,**  
**Patentanwaltskanzlei - Rechtsanwaltskanzlei,**  
**Holbeinstrasse 5**  
**81679 München (DE)**

(54) **XAF genes and polypeptides and their use for modulating apoptosis**

(57) The invention provides novel *XAF* nucleic acid sequences. Also provided are *XAF* polypeptides, anti-*XAF* antibodies, and methods for modulating apoptosis and detecting compounds which modulate apoptosis.

EP 0 892 048 A2